In vivo and in vitro drug interactions study of glimepride with atorvastatin and rosuvastatin

Journal of Young Pharmacists

Volumn 2, Issue 2, 2010, Pages 196-200

  Galani, V J ^a   Vyas, M ^b  

^a AR Patel and GH Patel Institute of Pharmacy   (India)

^b NONE

Author keywords

Atorvastatin; drug interaction; glimepride; rosuvastatin

Indexed keywords

ATORVASTATIN; GLIMEPIRIDE; ROSUVASTATIN;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; TANDEM MASS SPECTROMETRY;

EID: 78049403439     PISSN: 09751483     EISSN: 09751505     Source Type: Journal    
DOI: 10.4103/0975-1483.63169     Document Type: Article

References (15)

1. Krall LP, Beaser RS. Joslin Diabetes Manual. 12th ed. Philadelphia: Lea & Febiger; 1996.
2. O'Brien RC, Luo M, Balazs N, Mercuri J. In vitro and in vivo antioxidant properties of Gliclazide. J Diabetes Complications 2000;14:201-6.
3. Taskinen MR. Strategies for the management of diabetic dyslipidemia. Drugs 1998;58:47-51.
4. Vijan S, Hayward RA; American College of Physicians. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann Intern Med 2004;140:650-8.
5. Snow V, Aronson MD, Hornbake ER, Mottur-Pilson C, Weiss KB; Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Lipid control in the management of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2004;140:644-9.
6. Knopp RH, d'Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes. Diabetes Care 2006;29:1478-85.
7. Adsule SM, Baig MS, Gade PR, Khandelwal PN. A comparative evaluation of safety and efficacy of rosuvastatin, simvastatin, and atorvastatin in patients of type 2 diabetes mellitus with dyslipidemia. Int J Diabetes Dev Ctries 2009;29:74-9.
8. Langtry HD, Balfour JA. Glimepiride: a review of its use in the management of type 2 diabetes mellitus. Drugs 1998;55:563-84.
9. Malinowski JM. Atorvastatin: a hydroxymethylglutaryl-coenzyme A reductase inhibitor. Am J Health Syst Pharm 1998;55:2253-67.
10. White CM. A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol 2002;42:963-70.
11. Igel M, Sudhop T, Von-Bergmann K. Metabolism and drug interaction of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins). Eur J Clin Pharmacol 2001;57: 357-64.
12. Lin JH. Sense and nonsense in the prediction of drug-drug interactions. Curr Drug Metab 2000;1:305-31.
13. Zhang L, Zhang YD, Zhao P, Huang SM. Predicting drug-drug interactions: An FDA Perspective. AAPS J 2009;11:300-6.
14. Boxenbaum H, DiLea C. First time in human dose selection: allometric thoughts and perspectives. J Clin Pharmacol 1995;35:957-66.
15. Proudfoot SG. Assessment of bioavailability. 1 st ed. Pharmaceutics: The Science of Dosage form design. In: Aulton ME, editor. Edinburgh: Churchill Livingstone; 1999. p. 174-90.